Treatment of moderate to severe hypophosphatemia
▶BY INTRAVENOUS INFUSION
▶Adult: (consult product literature)
Established hypophosphataemia (with monobasic
potassium phosphate)
▶BY INTRAVENOUS INFUSION
▶Adult: 9 mmol every 12 hours, increased if necessary up
to 0.5 mmol/kg (max. per dose 50 mmol), increased
dose to be used in critically ill patients; dose to be
infused over 6–12 hours, according to severity
Vitamin D-resistant hypophosphataemic osteomalacia
▶BY MOUTH USING EFFERVESCENT TABLETS
▶Adult: 4–6 tablets daily, using Phosphate Sandoz ®.
PDF page 1138
GENERAL CAUTIONS Cardiac disease. dehydration.
diabetes mellitus. sodium and potassium concentrations
of preparations
SPECIFIC CAUTIONS
▶With intravenous use Avoid extravasation. severe tissue
necrosis
PDF page 1138
Phosphate
Sandoz ® contains sodium dihydrogen phosphate
anhydrous (anhydrous sodium acid phosphate) 1.936 g,
sodium bicarbonate 350 mg, potassium bicarbonate
315 mg, equivalent to phosphorus 500 mg (phosphate
16.1 mmol), sodium 468.8 mg (Na+ 20.4 mmol), potassium
123 mg (K+ 3.1 mmol); Polyfusor NA ® contains Na+
162 mmol/litre, K+ 19 mmol/litre, PO4
3- 100 mmol/litre;
non-proprietary potassium dihydrogen phosphate injection
(potassium acid phosphate) 13.6% may contain
1 mmol/mL phosphate, 1 mmol/mL potassium.
PDF page 1139
